News summary

Wave Life Sciences reports up to 88% reduction in obesity-related protein

Source: Longevity Technology • Published: 16 Nov 2026, 11:46

Summarized by Masters of Longevity from Longevity Technology.

WVE-007 markedly reduced circulating INHBE protein in early clinical updates.

Wave Life Sciences reports up to 88% reduction in obesity-related protein
Key Takeaways
  • WVE-007 is a GalNAc-siRNA targeting INHBE in humans.
  • Treatment produced reductions in circulating INHBE protein up to 88%.
  • Presented data were clinical updates, not pivotal trial results.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.